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Leipzig and Frankfurt, Germany; and Palermo, Mercogliano, and Padua, ItalyObjectives This study sought to evaluate the safety and performance of the Igaki-Tamai (Igaki Medical
Planning Company, Kyoto, Japan) biodegradable stent in patients with occlusive superﬁcial femoral
artery (SFA) disease.
Background Poly-L-lactic acid (PLLA) biodegradable stents have been shown to be effective in the
coronaries, but no data are available regarding their efﬁcacy in the femoral artery.
Methods A prospective, multicenter, nonrandomized study enrolled 30 patients with symptomatic de
novo SFA disease undergoing implantation of Igaki-Tamai bioresorbable stents. Clinical examinations
and duplex ultrasound were prospectively performed after 1, 6, 9, and 12 months. The main study
endpoints were technical success, restenosis rate, rate of target lesion revascularization (TLR), changes
in ankle-brachial index (ABI), and quality of life by evaluating the walking impairment questionnaire
(WIQ). Safety was assessed by monitoring the occurrence of major adverse clinical events and serious
adverse events.
Results The mean age of the patients was 67.7 years, and 77% were male. The mean lesion length
was 5.9 cm. Mean diameter stenosis was reduced from 89.9% to 6.2%, after stent implantation.
Technical success was 96.7%. Binary restenosis rate for the 6 and 12 months follow-up was 39.3% and
67.9%, respectively. The TLR rate was 25.0% after 6 months and 57.1% after 12 months. All TLR were
successful; the secondary patency rate after 1 year was 89.3%. Between baseline and 12 months, ABI
increased in 53.6% of patients. Functional endpoints (WIQ), even if affected by a relatively high
reintervention rate, showed improvement in most of the patients.
Conclusions The GAIA (Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatment
of De Novo Lesions in the Superﬁcial Femoral Artery) study shows that when using biodegradable
PLLA stents (Igaki-Tamai), the immediate angiographic results are comparable to the results of metal
stents, achieving a high secondary patency rate after 1 year. Modiﬁcations of stent characteristics and
technical modiﬁcations are needed with the goal to reduce the restenosis rate during the reabsorption
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306Endovascular therapy is 1 of the options endorsed by current local ethics committees. All patients provided written
guidelines (1,2) for the treatment of symptomatic femo-
ropopliteal artery disease. Especially for longer (>5 cm)
superﬁcial femoral artery (SFA) lesions, there is some evi-
dence that primary stenting yields higher patency rates than
after balloon angioplasty (3). Balloon angioplasty alone is
considered to be sufﬁcient for short SFA lesions by many
endovascular specialists (4,5). However, in case of subopti-
mal balloon angioplasty with ﬂow-limiting dissection or a
residual stenosis, a provisional stent implantation may be
necessary to stabilize the vessel wall and prevent acute or
subacute vessel reocclusion.See page 313The SFA represents a harsh environment for metallic
stents, because mechanical forces such as bending, torsion,
compression, and elongation occur during daily activities.
Concerns exist about stent fractures and their clinicalMedical, Medtronic, NDC, Occlutec
Recor, ResMed, Rox Medical, Sen
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Abbreviations
and Acronyms
ABI = ankle-brachial index
CI = conﬁdence interval
DUS = duplex ultrasound
PLLA = poly-L-lactic acid
SAE = serious adverse
event(s)
SFA = superﬁcial femoral
artery
TLR = target lesion
revascularization
WIQ = walking impairment
questionnaireimplications (6). Stents may also
hamper potential surgical or
endovascular future treatments.
Thus, the use of biodegradable
devices, which degrade over time
and leave only the remodeled
vessel, is a compelling concept:
“leaving nothing behind life-
long.” Therefore, the aim of this
study was to evaluate the safety
and performance of the biode-
gradable peripheral Igaki-Tamai
stent (Kyoto Medical Planning
Co., Kyoto, Japan) in the treat-
ment of de novo SFA lesions.Methods
Study design. A multicenter, prospective, nonrandomized
study (GAIA) was designed to evaluate the efﬁcacy and safety
of the biodegradable Igaki-Tamai stent in patients with de
novo atherosclerotic SFA disease. Subjects were evaluated
through 12 months following the implant procedure. Table 1
presents the inclusion/exclusion criteria.
The study was conducted according to the Guidelines
for Good Clinical Practices and has been approved by theh, Osprey, Ostial, PendraCare, Pfm Medical,
treHeart, Spectranetics, SquareOne, Trireme,
and Vessix; has received grant research support
has stock options with Cardiokinetix, Access
cal, Coherex, and SMT. All other authors have
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013; accepted September 26, 2013.informed consent before the procedure. An independent
clinical event committee was responsible for endpoint adju-
dication and safety monitoring.
Patient population. Thirty patients with atherosclerotic SFA
disease were treated with balloon angioplasty followed by
primary implantation of Igaki-Tamai bioresorbable stents.
All patients underwent baseline physical examinations with
a focus on manifestations of lower limb ischemia. The ankle-
brachial index (ABI) was measured and duplex ultrasound
(DUS) studies were performed, followed by selective angi-
ography of the infrainguinal arteries to outline the vascular
anatomy and deﬁne the lesion characteristics by visual
estimation.
Stent characteristics. The stent used in this study was the
peripheral Igaki-Tamai stent (Fig. 1A), which received
CE certiﬁcation in 2007 and has been available on
the European market since 2009. It is the only biodegrad-
able stent that is approved for the treatment of SFA lesions
in Europe.
The Igaki-Tamai stent is made of a biodegradable poly-
mer and marked with 2 radio-opaque markers, each one
being set at 2.0 mm from each end (Fig. 1B). The polymer
used is poly-L-lactic acid (PLLA), which is a bioabsorbable
material already in widespread clinical use with applications
such as resorbable sutures, soft-tissue implants, orthopedic
implants, and dialysis media (7). Degradation of PLLA
occurs predominantly via hydrolysis. The ﬁnal degradation
products of PLLA are eliminated from the body via the
Krebs cycle (mainly as carbon dioxide) and excreted in
the urine. For the ﬁrst 6 months, the stent retains its radial
strength and ﬂexibility to potentially prevent restenosis;
thereafter, the stent is bioabsorbed. A recent long-term
follow-up report (8) suggested that the Igaki-Tamai stent
required 3 years to disappear totally from human coronary
arteries.
Delivery is performed with a balloon-expandable system,
which is compatible with an 0.018-inch guidewire and a
7-F sheath. It is available in diameters of 5 to 6 mm and
in lengths of 37.8 and 78.8 mm. The 37.8-mm stent is
mounted on a 40-mm-long balloon, the 78.8-mm-long
stent is mounted on an 80-mm-long balloon.
Stent procedure and medication regimens. After passing the
lesions with conventional techniques, pre-dilation was
performed at the discretion of the interventionist. The
stent diameter was chosen to match the proximal reference
vessel diameter in a 1-to-1 ratio to ensure deployment close
to the stent’s nominal diameter, where it exerts its optimal
mechanical properties. When more than 1 stent was
needed to cover the lesion, the stents overlapped by 0.5
cm. Focal post-dilation was performed in case of residual
stenosis after stent deployment. The antithrombotic
regimen was pre-deﬁned as follows: periprocedural
anticoagulation with heparin according to the usual
Figure 1. The Igaki-Tamai Stent
(A) The Igaki-Tamai stent is made of poly-L-lactic acid (PLLA) monoﬁlament
with a zigzag helical design. (B) A ﬂuoroscopic image of the Igaki-Tamai stent
during implantation. The arrows indicate the proximal and distal gold
markers.
Table 1. Study Inclusion and Exclusion Criteria
Inclusion criteria
Age 18 yrs
Quality-of-life–limiting peripheral artery disease in combination with
a resting ABI of <0.8.
De novo SFA lesion with a diameter stenosis of >70%
Lesion length of 13 cm
Target vessel reference diameter 5 mm and 6 mm
Distal runoff deﬁned as minimal 1 patent infrapopliteal artery
Exclusion criteria
Minor or major tissue ulceration
Prior stenting in the intended target lesion
Impossibility to cross the target lesion
Acute or subacute occlusion of the target lesion
Treatment of ipsilateral lesions during the index procedure or
planned treatment after the index procedure
Any known allergies and/or intolerances to the following: ASA,
clopidogrel, heparin, contrast agents (that could not be adequately
pre-medicated)
Woman with childbearing potential without a negative pregnancy test
Life expectancy of <12 months
Any planned surgery within 30 days after the study procedure
Patient currently participating in another investigational drug or
device study
Severe renal failure (serum creatinine >2.5 mg/dl)
Myocardial infarction or stroke within 4 weeks before the procedure
ABI ¼ ankle-brachial index; ASA ¼ aspirin; SFA ¼ superﬁcial femoral artery.
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307institutional practices (5,000 U), and dual antiplatelet
therapy with clopidogrel and aspirin for 6 months after the
procedure, with the recommendation to continue aspirin
lifelong.
Follow-up and study endpoints. All patients were evaluated
before their discharge from the hospital, and were schedu-
led to return for ambulatory follow-up visits at 1, 6, 9, and
12 months after the index procedure. At the follow-up visits,
patients underwent physical examinations, assessment for
any adverse events, ABI measurements, and DUS for the
detection of restenoses.
The primary endpoint of this study was the in-stent binary
restenosis rate using DUS, performed by an independent
operator, at 1-, 6-, 9-, and 12-month follow-up visits. A
peak systolic velocity ratio 2.4, corresponding to a 50%
decrease in vessel diameter (9), was used for the diagnosis
of binary restenosis. Secondary endpoints were:
1. Technical success deﬁned as the ability to cross the
target lesion with the device and deploy the stent as
intended at the treatment site.
2. Improvement in ABI at rest of 0.15 compared with
the baseline assessment.
3. Changes in quality of life by comparing the walking
impairment score at 6 and 12 months follow-up with
the score at baseline.4. The occurrence of target lesion revascularization
(TLR), serious adverse events (SAE), and major
adverse clinical events up to 12 months follow-up.
Statistical analysis. Descriptive statistics were used to pre-
sent: 1) mean values and SD for continuous variables; 2)
median values (range); and 3) counts and percents for cat-
egorical variables. Binary restenosis, TLR, and patency rates
are presented as percents of sample size (numerator/de-
nominator). Mean ABI and walking impairment question-
naire (WIQ) were compared using the Student t test
for dependent samples. Analyses were performed using
SPSS software, version 20 (SPSS, Chicago, Illinois).Results
Thirty patients were enrolled in the study, at 4 different
sites. Most patients were male (76.7%), and mean age was
67.7  8.8 years. The baseline clinical characteristics
are shown in Table 2. Cardiovascular risk factors were
highly prevalent, including hypertension in 90.0%, current
or former smoking in 60.0%, and diabetes in 56.7% of
patients. The mean ABI at rest before intervention was
0.71  0.10.
Angiographic and procedural characteristics and immediate
results. Lesion and lesion treatment characteristics are pre-
sented in Table 3. The target lesions were mainly situated
Table 2. Baseline Patient Demographics (N ¼ 30)
Height, cm 30 (168.9  8.7)
Weight, kg 30 (79.1  9.6)
Age, yrs 30 (67.7  8.8)
Male 23 (76.7)
Smoking history
Never smoked 12 (40)
Previous smoker 11 (36.7)
Current smoker 7 (23.3)
Diabetes mellitus 17 (56.7)
No treatment 4 (23.5)
Oral medication 5 (29.4)
Insulin 7 (41.2)
Oral medication and insulin 1 (5.9)
Hypertension 27 (90.0)
Dyslipidemia 18 (60.0)
Renal failure* 6 (20.0)
Previous cerebrovascular event 3 (10)
Previous coronary artery disease 20 (66.7)
Previous MI 4 (20)
Angina pectoris 3 (15)
History of valve disease 2 (6.7)
Present or recurrent arrhythmias 5 (16.7)
Values are n (mean  SD) or n (%). *Serum creatinine >2.5 mg/dl.
MI ¼ myocardial infarction.





Proximal SFA 5 (16.7)
Mid SFA 13 (43.3)
Distal SFA 11 (36.7)
Mid and distal SFA 1 (3.33)
Target lesion occlusion 3 (10.0)
Pre-dilation performed 25 (83.3)
Lesion crossed with the device 30 (100)
Stent deployed at intended site 29 (96.7)
Post-dilation after stent implantation 5 (16.7)
Number of implanted stents: 39 (100)
5.0 mm/37.8 mm 3 (7.7)
5.0 mm/78.8 mm 8 (20.5)
6.0 mm/37.8 mm 8 (20.5)
6.0 mm/78.8 mm 20 (51.3)
RVD, mm 30 (5.3  0.4)
Diameter stenosis pre-procedure, % 30 (89.9  11.1)
Stenosis length, cm 30 (5.9  3.6)
Diameter stenosis post pre-dilation, % 25 (39.4  22.6)
Maximal stent inﬂation pressure, atm 30 (9.6  2.3)
Stent inﬂation duration, s 29 (95.0  54.0)
2nd stent maximal inﬂation pressure, atm 9 (10.0  1.0)
2nd stent inﬂation duration, s 9 (116.7  57.0)
Diameter stenosis post–stent implantation, % 30 (6.2  12.0)
Values are n (%) or n (mean  SD).
RVD ¼ reference vessel diameter; SFA ¼ superﬁcial femoral artery.
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308in the mid (46.7%) and distal (40.0%) SFA. On average,
the reference vessel diameter was 5.3  0.4 mm. The lesions
presented on average a diameter stenosis of 89.9  11.1%
and a length of 5.9  3.6 cm. In 25 subjects, pre-dilation
was performed, resulting in an mean diameter stenosis of
39.4  22.6% after pre-dilation.
For all patients, the lesion could be crossed with the de-
vice for stent deployment. In 1 patient, the stent could not
be deployed (the balloon did not inﬂate). The stent could
be retrieved, and another stent was implanted successfully.
Thus, the technical success rate was 96.7%. Twenty-
two subjects had 1 stent implanted, and 8 patients had
2 stents implanted. Nine patients were treated with
the 5-mm-diameter stent, and 21 subjects received the
6-mm-diameter stent. After stent implantation, the mean
diameter stenosis was reduced to 6.2%. Figure 2 shows the
ﬂuoroscopic images of a patient treated with the Igaki-
Tamai stent for SFA stenosis.
Safety assessment. Twenty-nine patients completed the
1-month follow-up, and 28 patients completed the
6-month, 9-month, and 12-month follow-up. One patient
was not willing to undergo the follow-up examination and
withdrew from the study; 1 patient died 57 days post-pro-
cedure due to heart failure and pneumonia. The clinical
event committee adjudicated this mortality as not related
to the procedure nor to the device. No other major adverse
clinical events were recorded during the observational
period.Until the 12 months follow-up, 34 SAE were recorded.
Sixteen SAE were not related to the device or procedure.
Eighteen TLR were classiﬁed as SAE. They have been
performed in 16 patients (2 patients received a TLR twice),
resulting in a 57.1% TLR rate after 1 year (Fig. 3). Table 4
lists the type of TLR.
Performance analysis. Until the 1-month follow-up, DUS
showed that in 2 patients (6.9%, 95% conﬁdence interval
[CI]: 0% to 17.2%), binary restenosis was present. At 6
months, there were 9 new cases with restenosis or reocclu-
sion, resulting in a binary restenosis rate of 39.3% (95%
conﬁdence interval: 20.7% to 55.2%). Restenosis rates for
the 9 and 12 months follow-up were 60.7% (95% CI:
41.4% to 75.9%) and 67.9% (95% CI: 48.3% to 82.8%),
respectively (Fig. 3). Primary patency and secondary patency
rates after 1 year were 32.1% and 89.3%. In all cases of
restenosis or reocclusion, it was possible to navigate a
guidewire through the obstructed stent without problems so
that all TLR were successful.
Mean ABI increased from 0.71 (0.10) at baseline to
0.93 (0.16) following treatment. ABI at the 1-month
follow-up was 0.89 (0.19). ABI at the 6-, 9-, and
12-month follow-up was 0.77 (0.21), 0.78 (0.19), and
Figure 2. Treatment With an Igaki-Tamai Stent
(A) Angiographic image of a high-grade stenosis of the superﬁcial femoral artery right leg. (B) Angiographic image obtained after implantation of an Igaki-Tamai stent.
(C) Angiographic image obtained after 2 years showing no restenosis.
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3090.89 (0.15), respectively. At 12 months, ABI was
improved 0.15 compared with baseline in 15 cases
(53.6%).
At screening, 29 patients completed the WIQ, whereas
at 6 and 12 months, 28 subjects answered the questions. At
6-month follow-up, 23 patients (82.1%) had an improved
walking capacity compared with baseline, and 20 patients
(71.4%) had improved their walking speed. The majority
of patients (26 patients, 92.9%) could climb stairs with
less trouble. At 12 months, all patients showed improve-
ments in walking distance compared with baseline capa-
city. Twenty-four patients (85.7%) showed improvementFigure 3. Graphic Display of the Binary Restenosis Rate and the
Rate of TLR
Shown are the rates at 1, 6, 9, and 12 months. TLR ¼ target lesion
revascularization.in walking speed, and 23 patients (82.1%) could climb
stairs with less trouble.
Histopathologic analysis of restenosis. Specimens of the
tissue that caused in-stent restenosis were retrieved by athe-
rectomy in 8 cases. The histological analysis (Fig. 4) showed
hyperplastic tissue, characterized by stellate or fusate myoﬁ-
broblasts, embedded in myxoid extracellular matrix. Rem-
nants of stent struts were found within the restenotic tissue in
3 cases (37.5%). Inﬂammatory cells were present in 4 cases
(50.0%), 2 of them with a foreign body reaction (giant cells
surrounding the struts), 1 with polymorphonucleated cells.
Thrombus was present in 4 cases (50.0%), and minimal
microcalciﬁcation was present in 1 case (12.5%).
Discussion
The concept of a biodegradable stent gained attention 1
decade ago, as the ﬁrst biodegradable stents were used in
the clinical setting. The Igaki-Tamai stent was the ﬁrst
in-human, fully biodegradable stent. Despite the ﬁrst
promising results in the coronary ﬁeld (10), the advent of
drug-eluting stents diverted attention from biodegradable
stents. However, the shortcomings of metallic stents are
evident in the coronaries as well as in the peripheral arteries.
The efﬁcacy of metallic stents in the coronaries is limited
because of the risk of late stent thrombosis, hampered
vascular remodeling, and impaired vasomotor function
distal to the implanted stent (7). For the peripheral arteries,
especially the SFA, major problems after implantation of
nitinol stents are the risk of stent fracture and the high
risk of recurrent in-stent stenosis caused by intima hyper-
plasia. Treatment of SFA in-stent restenosis is still a
Table 4. TLR




Atherectomy þ stent 2
Thrombolysis 1
Thrombolysis þ atherectomy 1
TLR ¼ target lesion revascularization.
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310challenge for endovascular therapy. A recent study (11) has
shown recurrent obstructions after restenosis in nitinol stents
in 50% to 85% of lesions at 2 years, depending on the
pattern of restenosis. On the basis of these limitations,
bioabsorbable stents came into focus again for coronary as
well as peripheral arteries (7).
Recently, the long-term (>10 years) clinical outcomes
after implantation of Igaki-Tamai stents in the coronariesFigure 4. Histopathology of the Restenotic Lesions
The retrieved material was excised by atherectomy after Igaki-Tamai stent implantat
thrombotic material (#) close to stent remnants (*). Hematoxylin-eosin stain, origina
broblasts and with an area of inﬂammation and neovascularization (inset) Hematox
inﬂamed area from B (inset). (C) Immunohistochemical staining showing myoﬁbrob
with neoangiogenesis (x). Anti-SMA antibody staining, original magniﬁcation 10. (D
original magniﬁcation 10. (E) Immunohistochemical staining for leukocyte commohave been published (8). The study reported a high survival
rate free of cardiac death (98% at 10 years), demonstrating
the long-term safety of this stent. After 10 years, the TLR
rate was 28%.
This study is the ﬁrst report, to our knowledge, on the
efﬁcacy and safety of a PLLA bioabsorbable stent in the
SFA. Similar to the results in the coronaries, the treatment
of symptomatic SFA lesions with the biodegradable Igaki-
Tamai stent was safe and effective in achieving favorable
acute angiographic results. Functional endpoints (WIQ),
even if affected by a relatively high reintervention rate,
were acceptable, showing improvement in most of the
patients in walking distance and speed, because of the high
secondary patency rate.
In fact, a high rate (67.9%) of recurrent obstruction of
the treated arterial segment was observed after 1 year.
Subsequently, repeat revascularization of the target lesion
was performed in 57.1% of cases within the observation
period, resulting in a secondary patency rate of 89.3%.ion. (A) Multiple fragments composed mainly of hyperplastic tissue and
l magniﬁcation 5. (B) Multiple fragments of hyperplastic tissue rich in myoﬁ-
ylin-eosin stain, original magniﬁcation 5. (C, D, E) High-power views of the
lasts positive for smooth muscle cell actin (SMA) embedded in myxoid material
) Immunohistochemical staining for macrophages. Anti-CD68 antibody staining,
n antibody (LCA). Anti-CD45 antibody staining, original magniﬁcation 10.
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311Compared with recently published trials, the Igaki-Tamai
stent did not match the patency rates of third-generation
nitinol stents. For example, the Edwards RESILIENT
(Randomized Study Comparing the Edwards Self-
Expanding Lifestent versus Angio-plasty Alone in Lesions
INvolving the SFA and/or Proximal Popliteal Artery) trial
(12) reported a 37% restenosis rate for the LifeStent (Bard
Peripheral Vascular, Tempe, Arizona), and the Astron trial
(13) reported a 1-year 34.4% restenosis rate for the Astron
stent (Biotronik, Berlin, Germany).
To further understand the pathophysiological mechanism
of in-stent restenosis in this cohort, we have investigated
the obstructive tissue that was obtained by atherectomy in 8
patients. The data of the histopathologic analyses supported
a hyperplastic restenotic response with a partial thrombotic
phenomenon in 50% of the cases.
Concerns have been raised about the possible induction
of an inﬂammatory response by PLLA or its degradation
products. van der Giessen et al. (14) reported a marked
inﬂammatory response after the implantation of 5 different
polymer stents, including lactic acid, in a porcine coronary
model. These concerns have not been supported by other
authors: Zidar et al. (15) reported a minimal inﬂammatory
reaction and minimal neointimal hyperplasia with the use of
PLLA stents in canine femoral arteries. Atherectomy of a
restenotic coronary lesion after treatment with the Igaki-
Tamai stent did not show any signiﬁcant inﬂammatory
response (8). These ﬁndings go along with the current
histopathologic analysis that showed the typical pattern of
smooth muscle cell proliferation (16) in the absence of
signiﬁcant inﬂammatory inﬁltration. Only in 2 of the 8
assessed cases could we observe a localized minimal foreign
body reaction, conﬁned to only some strut remnants.
The role of thrombus in restenosis is unclear. Schwartz
et al. (17) suggested that mural thrombus assumes a major
role in restenosis by providing an absorbable matrix into
which smooth muscle cells proliferate. Thrombus was in fact
observed in 4 of 8 specimens (50.0%) in the present cohort
and thus cannot be excluded as a factor contributing to
the genesis of SFA restenosis in the Igaki-Tamia stent.
Thrombolysis was used in 2 cases to recanalize an occluded
stent, which raises the question whether prothrombotic
properties of either the device or its degradation products
might play a role.
Another factor inﬂuencing long-term patency is the
stent’s radial force, which is needed to withstand compres-
sion from outside, caused by, for example, calciﬁed plaques.
Compared with cobalt chromium, nitinol, and other mate-
rials that are currently being used in stent fabrication,
bioabsorbable candidates are substantially inferior from a
mechanical strength perspective (18). In our study, however,
relevant recoil after stent implantation was not observed,
with an mean diameter stenosis post-stenting of only 6.2%.
This suggests that the mechanical properties of the Igaki-Tamai stents were sufﬁcient to withstand compression in
this cohort without extreme calciﬁcation.
This study is the ﬁrst report on the treatment of athero-
sclerotic SFA lesion with a bioabsorbable stent. There has
been 1 published work (19) evaluating an absorbable mag-
nesium-alloy stent (AMS, Biotronik, Berlin, Germany) in
the infrapopliteal arteries. Although the study indicated
that the AMS technology can be safely applied, it did not
demonstrate efﬁcacy, with a binary restenosis rate of 68.2%
for the magnesium alloy stent after 6 months.
Study limitations. Limitations of the current study are
related to its nonrandomized design, which makes a direct
comparison to other treatment modalities impossible. Addi-
tionally, the systematic DUS may have led to a higher
TLR rate, because some cases of TLR may have been driven
by DUS results and not by ischemia problems. Finally, this
study shows that the biodegradable Igaki-Tamai stent can
achieve an immediate angiographic result similar to the
result of other metal stents. Modiﬁcations of stent charac-
teristics (e.g., drug-eluting properties) or combination with
other treatment modalities (e.g., atherectomy, drug-coated
balloons) are needed to optimize the results, while leaving
nothing behind.
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